Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
AstraZeneca Signs Two Research Pacts
by Jean-François Tremblay
October 28, 2013
| A version of this story appeared in
Volume 91, Issue 43
AstraZeneca will team up on drug R&D with two organizations. German drug discovery firm Evotec will provide AstraZeneca with molecules that might be effective against chronic kidney diseases. AstraZeneca is making an up-front payment to Evotec and could make milestone payments. In Taiwan, AstraZeneca has joined with the National Research Program for Biopharmaceuticals, a government-funded drug discovery organization. NRPB will work with research groups in Taiwan to find alternative therapeutic uses for existing AstraZeneca compounds.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X